このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Neith マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

Chun Wu

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	no data
CEOの所有権	n/a
経営陣の平均在職期間	データなし
取締役会の平均在任期間	データなし

経営陣の近況

Recent updates

A Look At The Fair Value Of Come True Biomedical Inc. (GTSM:6236)

Mar 02

CEO（最高経営責任者

Chun Wu

no data

在職期間

Mr. Chun Yi Wu serves as Chief Executive Officer and Chairman of Come True Biomedical Inc.

Neith マネジメント

マネジメント基準チェック /04

主要情報

経営陣の近況

Neith Corporation, Annual General Meeting, Jun 26, 2024

Recent updates

First quarter 2024 earnings released: NT$0.27 loss per share (vs NT$0.31 loss in 1Q 2023)

Neith Corporation, Annual General Meeting, Jun 26, 2024

Full year 2023 earnings released: NT$0.96 loss per share (vs NT$0.73 loss in FY 2022)

New major risk - Share price stability

Third quarter 2023 earnings released: NT$0.23 loss per share (vs NT$0.42 loss in 3Q 2022)

Second quarter 2023 earnings released: NT$0.14 loss per share (vs NT$0.037 profit in 2Q 2022)

Third quarter 2022 earnings released: NT$0.43 loss per share (vs NT$0.058 loss in 3Q 2021)

First quarter 2022 earnings released: EPS: NT$0.02 (vs NT$0.068 loss in 1Q 2021)

Full year 2021 earnings released: NT$0.17 loss per share (vs NT$0.34 loss in FY 2020)

Third quarter 2021 earnings released: NT$0.06 loss per share (vs NT$0.17 loss in 3Q 2020)

Second quarter 2021 earnings released: NT$0.06 loss per share (vs NT$0.12 loss in 2Q 2020)

First quarter 2021 earnings released: NT$0.07 loss per share (vs NT$0.063 loss in 1Q 2020)

Full year 2020 earnings released: NT$0.34 loss per share (vs NT$0.55 loss in FY 2019)

A Look At The Fair Value Of Come True Biomedical Inc. (GTSM:6236)

New 90-day low: NT$8.51

New 90-day high: NT$10.65

New 90-day low: NT$9.06

Third quarter 2020 earnings released: NT$0.17 loss per share

First half earnings released

CEO（最高経営責任者

在職期間

Neith マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Neith Corporation, Annual General Meeting, Jun 26, 2024

Recent updates

First quarter 2024 earnings released: NT$0.27 loss per share (vs NT$0.31 loss in 1Q 2023)

Neith Corporation, Annual General Meeting, Jun 26, 2024

Full year 2023 earnings released: NT$0.96 loss per share (vs NT$0.73 loss in FY 2022)

New major risk - Share price stability

Third quarter 2023 earnings released: NT$0.23 loss per share (vs NT$0.42 loss in 3Q 2022)

Second quarter 2023 earnings released: NT$0.14 loss per share (vs NT$0.037 profit in 2Q 2022)

Third quarter 2022 earnings released: NT$0.43 loss per share (vs NT$0.058 loss in 3Q 2021)

First quarter 2022 earnings released: EPS: NT$0.02 (vs NT$0.068 loss in 1Q 2021)

Full year 2021 earnings released: NT$0.17 loss per share (vs NT$0.34 loss in FY 2020)

Third quarter 2021 earnings released: NT$0.06 loss per share (vs NT$0.17 loss in 3Q 2020)

Second quarter 2021 earnings released: NT$0.06 loss per share (vs NT$0.12 loss in 2Q 2020)

First quarter 2021 earnings released: NT$0.07 loss per share (vs NT$0.063 loss in 1Q 2020)

Full year 2020 earnings released: NT$0.34 loss per share (vs NT$0.55 loss in FY 2019)

A Look At The Fair Value Of Come True Biomedical Inc. (GTSM:6236)

New 90-day low: NT$8.51

New 90-day high: NT$10.65

New 90-day low: NT$9.06

Third quarter 2020 earnings released: NT$0.17 loss per share

First half earnings released

CEO（最高経営責任者

在職期間

マネジメント基準チェック /04